A Critical Analysis of the Clinical Use of Incretin|Based Therapies

A critical analysis of the clinical use of incretin-based therapies

There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) ...

A Critical Analysis of the Clinical Use of Incretin-Based Therapies

Dr. Nauck provides a defense of incretin-based therapies and that the benefits clearly outweigh any concern of risk.

A Critical Analysis of the Clinical Use of Incretin-Based Therapies

Along the same lines, long-term treatment in obese human subjects with high liraglutide doses up to 3-mg per day does not lead to elevations in ...

Comment on: Butler et al. A Critical Analysis of the Clinical Use of ...

... Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? ... refer to these data as treatment being stopped 2 weeks before the evaluation ...

A Critical Analysis of the Clinical Use of Incretin-Based Therapies

A Critical Analysis of the Clinical Use of Incretin-Based Therapies · Abstract and Figures · Citations (192) · References (61) · Recommended publications.

Clinical Application of Incretin-Based Therapy: Therapeutic Potential ...

Table 1 provides a summary of the clinical effects of both GLP-1 receptor agonists and DPP-4 inhibitors. Although the list of effects is not exhaustive, it ...

Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based ...

Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125.

Clinical Application of Incretin-Based Therapy: Therapeutic Potential ...

Table 1 provides a summary of the clinical effects of both. GLP-1 receptor agonists and DPP-4 inhibitors. Although the list of effects is not exhaustive, it ...

Incorporating Incretin-Based Therapies into Clinical Practice for ...

A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36:2118–25. Article ...

A Review of Incretin Therapies Approved and in Late-Stage ...

had 2 coprimary end points: change in body weight and change in the Kansas City Cardiomyopathy Questionnaire clinical summary score. c. STEP 1, STEP 3-5, STEP 8 ...

Clinical Application of Incretin-Based Therapy: Therapeutic Potential ...

Clinical Use of Incretin Based Therapy: A Practical Summary. Effective therapies for diabetes exist, but therapies that are even more effective, safer, and ...

An Update on the Effect of Incretin-Based Therapies on β-Cell ...

Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a ...

Incretin therapies: highlighting common features and differences in ...

A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013 ...

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes

Careful postmarketing surveillance for adverse effects, especially among the DPP4 inhibitors, and continued evaluation in longer-term studies and in clinical ...

Glucagon-like peptide 1-based therapies for the treatment of type 2 ...

This topic will review the mechanism of action and therapeutic utility of GLP-1-based therapies for the treatment of type 2 diabetes mellitus.

Tirzepatide Once Weekly for the Treatment of Obesity

Download a PDF of the Research Summary. Results. At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of ...

Cardiovascular outcomes trials with incretin-based medications

... therapies (IBTs) have become treatment widely used treatment option in clinical practice. ... review articles, clinical trials, meta-analysis and poster ...

Glucagon-like peptide-1 receptor: mechanisms and advances in ...

This mechanism is particularly evident in the use of GLP-1-based drugs, such as GLP-1RAs, in the treatment of T2DM. In summary, the relatively ...

UpToDate: Trusted, evidence-based solutions for modern healthcare

The heart of UpToDate is over 7,400 expert clinicians, editors, and reviewers who review and assemble the latest clinical, drug, and patient and member ...

CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI

They have also come under criticism for their cost, which, in the case of the most recently approved CAR T-cell therapy, is more than $450,000.